Evidence map›Paper›PMID 40273463›Full record

Observational studyRevista medica del Instituto Mexicano del Seguro Social2025

[Innate immune response to interferon gamma in severe Covid-19 positive patients].

Fabiola Del Rocío Villalobos-Gómez, Anastacio Palacios-Marmolejo, Rogelio Salinas-Gutiérrez, Hugo Enrique Lagunes-Servín

Abstract readEnglish AbstractObservational Study
In one paragraph

Observational study in Revista medica del Instituto Mexicano del Seguro Social, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Fabiola Del Rocío Villalobos-GómezInstituto Mexicano del Seguro Social, Hospital General de Zona No. 3, Servicio de Patología. Aguascalientes, Aguascalientes, México.ORCID 0000-0002-9082-1827
Anastacio Palacios-MarmolejoInstituto de Salud del Estado de Aguascalientes, Laboratorio Estatal de Aguascalientes, Laboratorio de Biología Molecular. Aguascalientes, Aguascalientes, México.ORCID 0009-0006-9353-0765
Rogelio Salinas-GutiérrezUniversidad Autónoma de Aguascalientes, Centro de Ciencias Básicas, Departamento de Estadística. Aguascalientes, Aguascalientes, México.ORCID 0000-0002-1669-4460
Hugo Enrique Lagunes-ServínInstituto de Salud del Estado de Aguascalientes, Departamento de Investigación y Enseñanza. Aguascalientes, Aguascalientes, México.ORCID 0000-0002-5843-3795

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: SARS-CoV-2 is associated with the activation of innate immunity, with an observed increase in neutrophils, mononuclear phagocytes, and natural killer cells, as well as a decrease in T cells. Interferon plays important roles in restricting viruses and is crucial because it participates in both innate and adaptive immunity. Gamma interferon (IFN-γ) is a cytokine that plays a fundamental role in maintaining homeostasis in the body, both in vitro and in vivo. Objective: An immunological study was conducted to measure the concentrations of IFN-γ in severe SARS-CoV-2-positive patients. Material and methods: Around 500 sera from patients with similar respiratory comorbidities at the onset of the disease were analyzed, using healthy patients as controls. The sera from SARS-CoV-2-positive individuals were processed using the ELISA technique, and the statistical treatment of the data involved creating a database with the absorbance readings, which were then converted into concentrations in pg/ml. Results: We can infer that the amount of IFN-γ expression depends on the patient's condition; the more severe the patient's condition, the higher the expression of this cytokine compared to their baseline levels, ranging from 0 to 0.5 μg/ml. Conclusion: It is suggested that the IFN-γ response plays an important role in controlling the disease, and effective therapies are recommended for the treatment of Covid-19, which will lead to the implementation of therapeutic approaches aimed at counteracting the immune system, especially in the more severe forms of the disease.

Indexed as

COVID-19Immunity, InnateInterferon-gammaSARS-CoV-2AdultAgedCase-Control StudiesFemaleHumansMaleMiddle AgedSeverity of Illness IndexInterferon-gammaCOVID-19ImmunityInterferon gamma

Identifiers

PMID40273463
PMCPMC12165371

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.